Full Text

Turn on search term navigation

© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression‐free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment‐emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real‐life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.

Details

Title
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
Author
Fazio, Francesca 1 ; Franceschini, Luca 2 ; Tomarchio, Valeria 3 ; Rago, Angela 4 ; Garzia, Maria Grazia 5 ; Cupelli, Luca 6 ; Bongarzoni, Velia 7 ; Andriani, Alessandro 8 ; Gumenyuk, Svitlana 9 ; Tafuri, Agostino 10 ; Siniscalchi, Agostina 11 ; Piciocchi, Alfonso 12 ; De Fabritiis, Paolo 13 ; De Rosa, Luca 14 ; Tommaso Caravita di Toritto 15 ; Annibali, Ombretta 16 ; Cantonetti, Maria 17 ; Petrucci, Maria Teresa 1 

 Department of Translational and Precision Medicine, Hematology, Azienda Policlinico Umberto I, Sapienza University of RomeSapienza Università di Roma 
 Transplant Network, Hematology‐Stem Cell Transplant Unit, Rome, Italy 
 Department of Haematology, University Campus Biomedico, Rome, Italy 
 ASL RM/A, UOSD Ematologia Asl Roma 1, Rome, Italy 
 Department of Hematology, Hematology, San Camillo Forlanini Hospital, Rome, Italy 
 Department of Hematology, Hematology, Ospedale Sant'Eugenio, Rome, Italy 
 Department of Hematology, San Giovanni‐Addolorata Hospital, Rome, Italy 
 Department of Hematology, Ospedale Fabrizio Spaziani, Rome, Italy 
 Haematology and Stem Cell Transplant, Regina Elena National Cancer Institute, Rome, Italy 
10  Azienda Ospedaliera Sant'Andrea, Rome, Italy 
11  S. Eugenio Hospital, Institute of Haematology, Rome, Italy 
12  Data Center, Italian Group for Adult Hematologic Diseases, (GIMEMA), Rome, Italy 
13  Department of Haematology, Ospedale Sant'Eugenio, Rome, Italy 
14  Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliera San Camillo‐Forlanini, Rome, Italy 
15  Department of Hematology, ASL Roma 1, Rome, Italy 
16  Department of Haematology, Campus Bio‐Medico University of Rome, Rome, Italy 
17  Chair of Hematology, Universita Tor Vergata, Rome, Italy 
Pages
121-128
Section
HAEMATOLOGIC MALIGNANCY ‐ PLASMA CELL
Publication year
2022
Publication date
Feb 2022
Publisher
John Wiley & Sons, Inc.
e-ISSN
26886146
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2625093666
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.